Skip to main content

editorial

. 2008 Oct 1;5(4):497–498. doi: 10.1016/j.nurt.2008.08.010

New treatments for neuromuscular disease: Optimism and obstacles

Hanns Lochmüller ^1,^✉, Robert C Griggs ²

PMCID: PMC4514702 PMID: 19019299

The content is available as a PDF (48.8 KB).

References

1.Müller JS, Mihaylova V, Abicht A, Lochmüller H. Congenital myasthenic syndromes: spotlight on genetic defects of neuromuscular transmission. Expert Rev Mol Med. 2007;9:1–20. doi: 10.1017/S1462399407000427. [DOI] [PubMed] [Google Scholar]
2.Thirion C, Lochmüller H. Current status of gene therapy for muscle diseases. Drug News Perspect. 2007;20:357–363. doi: 10.1358/dnp.2007.20.6.1138159. [DOI] [PubMed] [Google Scholar]
3.Rifai Z, Welle S, Moxley RT, Lorenson M, Griggs RC. Effect of prednisone on protein metabolism in Duchenne dystrophy. Am J Physiol. 1995;268:E67–E74. doi: 10.1152/ajpendo.1995.268.1.E67. [DOI] [PubMed] [Google Scholar]
4.Griggs RC, Moxley RT, editors. Treatment of neuromuscular diseases. New York: Raven Press; 1977. [Google Scholar]

ACTIONS

RESOURCES